Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Myelodysplastic Syndromes
Conditions
Keywords
Ki-67
Brief summary
Ki-67 is used as a marker for determination of the proliferative activity in solid tumors. The use within hemato-oncological malignancies is limited. This is related to limited technical possibilities of flow cytometry in the past. Meanwhile, flow cytometry in hemato-oncological malignancies has progressed to assessment of 8 colors and makes it possible to add Ki-67 as an additional marker to the 8-color panels. Adding Ki-67 to these panels could lead to improved diagnosis and prediction of therapy response for a number of hemato-oncological malignancies.
Interventions
DIAGNOSTIC_TESTFlow cytometry
Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
Sponsors
Zuyderland Medisch Centrum
Maastricht University Medical Center
Maastricht University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* MDS and AML patients
Exclusion criteria
* Ongoing radio- and/or chemotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maturation patterns diagnosis | 5 years | Maturation patterns based on immunophenotype for red blood cells and several types of immune cells and their respective contributions to diagnosis. Maturation patterns are scored by various methods/combinations to form diagnostic score. A higher diagnostic score will lead to a more likely diagnose for MDS and/or AML. |
| Proliferative index diagnosis | 5 years | Ki-67 proliferative index (within populations and maturation) and its contribution to diagnosis. A lower Ki-67 proliferative index will lead to a more likely diagnose for MDS and/or AML. |
| Proliferative index prognosis | 5 years | Ki-67 as prognostic parameter. A lower Ki-67 proliferative index will (hypothetically) lead to worse prognosis for MDS and AML in terms of: transfusion dependence (expressed in amount of transfusions in 2 months), chemotherapy response (expressed as total remission, normalization of blood values, possibly also normalization of cytogenetics in bone marrow cells), overall survival (expressed in months after diagnosis), Risk scores. Higher risk scores are correlated with worse prognosis. |
Contacts
Primary ContactMathie Leers, Dr.
Backup ContactBart de Wit, Dr.
Outcome results
None listed